TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02390453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive and Physical
Description: Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive
Description: Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical
Description: Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Control modules provide social contact for group discussion of health and successful aging.
Study: NCT03921853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
Study: NCT02130323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 12.5mg (5%) once a week vaginally for 16 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loop Electrosurgical Excision Procedure
Description: Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
Study: NCT03617900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Lactose monohydrate 400 mg/capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 500 mg paracetamol. use in need

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 500 mg paracetamol. use in need

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: 500 mg paracetamol. use in need
Study: NCT02879526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CPT
Description: Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
Study: NCT04255472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO Caregiver skills training (CST) program
Description: Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
Study: NCT02463513

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 2 week placebo washout + 16 weeks intervention (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.6mg riboflavin (Vitamin B2)
Description: 2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10mg riboflavin (Vitamin B2)
Description: 2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
Study: NCT02537756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
Study: NCT02918162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosed IV at 200mg every 21 days per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy regimen
Description: Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily.
Study: NCT04238520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functionally Tailored Oral Care Intervention
Description: Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Intervention
Description: Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
Study: NCT03363295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Injection
Description: One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
Study: NCT04255472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
Study: NCT03911934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polypharmacy intervention
Description: A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
Study: NCT03409757

Intervention type: DRUG
Intervention: Velphoro
Description: 4 weeks

Intervention type: OTHER
Intervention: saliva collection
Description: 2 samples

Intervention type: OTHER
Intervention: saliva collection
Description: 2 samples

Intervention type: OTHER
Intervention: Supragingival biofilm collection
Description: 2 samples

Intervention type: OTHER
Intervention: Supragingival biofilm collection
Description: 2 samples

Intervention type: OTHER
Intervention: stool collection
Description: 2 samples

Intervention type: OTHER
Intervention: stool collection
Description: 2 samples

Intervention type: OTHER
Intervention: blood collection
Description: 2 samples
Study: NCT01604681

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Oil
Description: 6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
Study: NCT03688230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abituzumab
Description: 1000 mg IV

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cetuximab + FOLFIRI
Description: 400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
Study: NCT00780520

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alanine-glutamine infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alanine-glutamine infusion
Study: NCT03911934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
Study: NCT02986009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting
Description: The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
Study: NCT02295709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNR steroid (dexamethasone) injection
Description: deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTF steroid (dexamethasone) injection
Description: deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTF steroid (dexamethasone) injection
Description: deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One of the most efficient steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One of the most efficient steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One of the most efficient steroids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C arm
Description: the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C arm
Description: the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C arm
Description: the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
Study: NCT04165720

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Online questionnaire via SoSciSurvey
Study: NCT03726463

Intervention type: PROCEDURE
Intervention: Kidney transplantation
Description: Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
Study: NCT03849599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-300
Description: Treatment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study: NCT01206842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in Affect Recognition
Description: A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
Study: NCT02806921

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZenLens
Description: The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZenLens
Description: The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Study: NCT00761592

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 900kDa
Description: 6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 150kDa
Description: 6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
Study: NCT00218179

Intervention type: OTHER
Intervention: Non-intervention
Description: Measured total NNAL and PheT as biomarkers of exposure

Intervention type: OTHER
Intervention: Non-intervention
Description: Measured total NNAL and PheT as biomarkers of exposure
Study: NCT00922779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180micrograms sc weekly for 12-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
Study: NCT02627027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-395 0.25/750mg
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-395 0.25/750mg
Description: oral administration
Study: NCT04138459

Intervention type: OTHER
Intervention: Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services
Description: Explore recovery orientation of mental health services in a municipality through:~1. Qualitative, in-depth interviews with service users and mental health professionals and~2. Observational fieldwork
Study: NCT01977092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing case management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resource referrals
Study: NCT01784042

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary energy restriction
Study: NCT03198013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791826
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791826
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT00817622

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA, Vitamin E
Description: EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA, Vitamin E
Description: EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA, Vitamin E
Description: EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA, Vitamin E
Description: EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
Study: NCT05390008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Pilates Exercise
Description: Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching.
Study: NCT04424147

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HVA Regimens as Salvage Treatment
Description: venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
Study: NCT02427854

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education by animated training video
Description: Training performed by watching an animated educational video.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interactive hands-on bedside training
Description: Training performed as a traditional bedside training supported by a trainer in person.